171 related articles for article (PubMed ID: 26892349)
1. Intra- and interspecies gene expression models for predicting drug response in canine osteosarcoma.
Fowles JS; Brown KC; Hess AM; Duval DL; Gustafson DL
BMC Bioinformatics; 2016 Feb; 17():93. PubMed ID: 26892349
[TBL] [Abstract][Full Text] [Related]
2. Prospective clinical trial testing COXEN-based gene expression models of chemosensitivity in dogs with spontaneous osteosarcoma.
Gustafson DL; Collins KP; Fowles JS; Ehrhart EJ; Weishaar KM; Das S; Duval DL; Thamm DH
Cancer Chemother Pharmacol; 2021 Oct; 88(4):699-712. PubMed ID: 34263337
[TBL] [Abstract][Full Text] [Related]
3. Characterization of canine osteosarcoma by array comparative genomic hybridization and RT-qPCR: signatures of genomic imbalance in canine osteosarcoma parallel the human counterpart.
Angstadt AY; Motsinger-Reif A; Thomas R; Kisseberth WC; Guillermo Couto C; Duval DL; Nielsen DM; Modiano JF; Breen M
Genes Chromosomes Cancer; 2011 Nov; 50(11):859-74. PubMed ID: 21837709
[TBL] [Abstract][Full Text] [Related]
4. Gene expression profiling of canine osteosarcoma reveals genes associated with short and long survival times.
Selvarajah GT; Kirpensteijn J; van Wolferen ME; Rao NA; Fieten H; Mol JA
Mol Cancer; 2009 Sep; 8():72. PubMed ID: 19735553
[TBL] [Abstract][Full Text] [Related]
5. Reference gene validation for gene expression normalization in canine osteosarcoma: a geNorm algorithm approach.
Selvarajah GT; Bonestroo FAS; Timmermans Sprang EPM; Kirpensteijn J; Mol JA
BMC Vet Res; 2017 Nov; 13(1):354. PubMed ID: 29178874
[TBL] [Abstract][Full Text] [Related]
6. Global gene expression analysis of canine osteosarcoma stem cells reveals a novel role for COX-2 in tumour initiation.
Pang LY; Gatenby EL; Kamida A; Whitelaw BA; Hupp TR; Argyle DJ
PLoS One; 2014; 9(1):e83144. PubMed ID: 24416158
[TBL] [Abstract][Full Text] [Related]
7. Pre-clinical evaluation of proteasome inhibitors for canine and human osteosarcoma.
Patatsos K; Shekhar TM; Hawkins CJ
Vet Comp Oncol; 2018 Dec; 16(4):544-553. PubMed ID: 29998615
[TBL] [Abstract][Full Text] [Related]
8. Enrofloxacin enhances the effects of chemotherapy in canine osteosarcoma cells with mutant and wild-type p53.
York D; Withers SS; Watson KD; Seo KW; Rebhun RB
Vet Comp Oncol; 2017 Sep; 15(3):1087-1100. PubMed ID: 27333821
[TBL] [Abstract][Full Text] [Related]
9. A genome-wide approach to comparative oncology: high-resolution oligonucleotide aCGH of canine and human osteosarcoma pinpoints shared microaberrations.
Angstadt AY; Thayanithy V; Subramanian S; Modiano JF; Breen M
Cancer Genet; 2012 Nov; 205(11):572-87. PubMed ID: 23137772
[TBL] [Abstract][Full Text] [Related]
10. Prognostic and predictive biomarkers of canine osteosarcoma.
Selvarajah GT; Kirpensteijn J
Vet J; 2010 Jul; 185(1):28-35. PubMed ID: 20493743
[TBL] [Abstract][Full Text] [Related]
11. Tumor suppressor PTEN is mutated in canine osteosarcoma cell lines and tumors.
Levine RA; Forest T; Smith C
Vet Pathol; 2002 May; 39(3):372-8. PubMed ID: 12014501
[TBL] [Abstract][Full Text] [Related]
12. Long noncoding RNA expression profiles of the doxorubicin-resistant human osteosarcoma cell line MG63/DXR and its parental cell line MG63 as ascertained by microarray analysis.
Zhu KP; Zhang CL; Shen GQ; Zhu ZS
Int J Clin Exp Pathol; 2015; 8(8):8754-73. PubMed ID: 26464619
[TBL] [Abstract][Full Text] [Related]
13. Use of an artificial lymphatic system during carboplatin infusion to improve canine osteosarcoma blood flow and clinical response.
DiResta GR; Aiken SW; Brown HK; Bergman PJ; Hohenhaus A; Ehrhart EJ; Baer K; Healey JH
Ann Surg Oncol; 2007 Aug; 14(8):2411-21. PubMed ID: 17503157
[TBL] [Abstract][Full Text] [Related]
14. Tumourigenic canine osteosarcoma cell lines associated with frizzled-6 up-regulation and enhanced side population cell frequency.
de Sá Rodrigues LC; Holmes KE; Thompson V; Newton MA; Stein TJ
Vet Comp Oncol; 2017 Mar; 15(1):78-93. PubMed ID: 25689105
[TBL] [Abstract][Full Text] [Related]
15. Osteoprotegerin activates osteosarcoma cells that co-express RANK and RANKL.
Marley K; Bracha S; Seguin B
Exp Cell Res; 2015 Oct; 338(1):32-8. PubMed ID: 26254896
[TBL] [Abstract][Full Text] [Related]
16. Inactivation of p53 and retinoblastoma family pathways in canine osteosarcoma cell lines.
Levine RA; Fleischli MA
Vet Pathol; 2000 Jan; 37(1):54-61. PubMed ID: 10643981
[TBL] [Abstract][Full Text] [Related]
17. TP53 gene mutations in canine osteosarcoma.
Kirpensteijn J; Kik M; Teske E; Rutteman GR
Vet Surg; 2008 Jul; 37(5):454-60. PubMed ID: 18986312
[TBL] [Abstract][Full Text] [Related]
18. Antioxidant 1 copper chaperone gene expression and copper levels in dog osteosarcoma patients.
Rivera PL; Li WT; Bhogal S; Mandell JB; Belayneh R; Hankins ML; Payne JT; Watters RJ; Weiss KR
Vet Comp Oncol; 2023 Sep; 21(3):559-564. PubMed ID: 37148200
[TBL] [Abstract][Full Text] [Related]
19. Immunohistochemical Validation of Spontaneously Arising Canine Osteosarcoma as a Model for Human Osteosarcoma.
Al-Khan AA; Gunn HJ; Day MJ; Tayebi M; Ryan SD; Kuntz CA; Saad ES; Richardson SJ; Danks JA
J Comp Pathol; 2017 Nov; 157(4):256-265. PubMed ID: 29169619
[TBL] [Abstract][Full Text] [Related]
20. Cathepsin K expression and activity in canine osteosarcoma.
Schmit JM; Pondenis HC; Barger AM; Borst LB; Garrett LD; Wypij JM; Neumann ZL; Fan TM
J Vet Intern Med; 2012; 26(1):126-34. PubMed ID: 22171552
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
